Priyanka Mandava

With over 16 years of Clinical Research/Development Experience, Priyanka joined Biomea Fusion in March of 2022 as Vice President, Clinical Operations. Priyanka brings with her in-depth knowledge of clinical research operations, including the interpretation and implementation of ICH/GCP guidelines as well as the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other Health Authority (HA) regulations. Throughout her career, Priyanka has contributed to the global approval of two blockbuster drugs (Imbruvica and Sofosbuvir) and several sNDAS.

Priyanka holds a Master’s Degree in Biotechnology and was most recently the Vice President, Global Clinical Operations at Summit Therapeutics where she provided leadership and strategic direction to the Clinical Operations team and oversaw the Phase III and Phase II studies in C.Diff. Prior to Summit, Priyanka worked at AbbVie/Pharmacyclics as the Director, Clinical Operations/Program Development where she oversaw and lead multiple hematology and solid tumor early to late phase programs with Imbruvica and multiple early phase molecules. In addition, Priyanka managed multiple collaborations with pharmaceutical companies and cooperative groups. Priyanka also worked on infectious disease (Hepatitis B & Hepatitis C) Phase III & IV studies at Gilead with Truvada, Tenofovir, and sofosbuvir.